Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 365

1.

Survivors of primary breast cancer 5 years after surgery: follow-up care, long-term problems, and treatment regrets. Results of the prospective BRENDA II-study.

Leinert E, Kreienberg R, Wöckel A, Kühn T, Flock F, Felberbaum R, Janni W, Taylor K, Singer S, Schwentner L; BRENDA study group.

Arch Gynecol Obstet. 2020 Jan 27. doi: 10.1007/s00404-020-05437-1. [Epub ahead of print]

PMID:
31989290
2.

Does chemotherapy improve survival in patients with nodal positive luminal A breast cancer? A retrospective Multicenter Study.

Herr D, Wischnewsky M, Joukhadar R, Chow O, Janni W, Leinert E, Fink V, Stüber T, Curtaz C, Kreienberg R, Blettner M, Wollschläger D, Wöckel A.

PLoS One. 2019 Jul 8;14(7):e0218434. doi: 10.1371/journal.pone.0218434. eCollection 2019.

3.

[Medicine and Economy: Measures for a Science Based, Patient-Centred and Resource Conscious Care. The Association of Scientific Medical Societies' (AWMF) Strategy Paper].

Nothacker M, Busse R, Elsner P, Fölsch UR, Gogol M, Jungehülsing GJ, Kopp I, Marckmann G, Maschmann J, Meyer HJ, Miller K, Wagner W, Wienke A, Zimmer KP, Kreienberg R.

Dtsch Med Wochenschr. 2019 Jul;144(14):990-996. doi: 10.1055/a-0891-3940. Epub 2019 May 16. German.

4.

Association between cognitive impairment and guideline adherence for application of chemotherapy in older patients with breast cancer: Results from the prospective multicenter BRENDA II study.

Leinert E, Schwentner L, Blettner M, Wöckel A, Felberbaum R, Flock F, Kühn T, Denkinger MD, Janni W, Kreienberg R, Singer S; BRENDA Study Group.

Breast J. 2019 May;25(3):386-392. doi: 10.1111/tbj.13231. Epub 2019 Apr 3.

PMID:
30945393
5.

Does the number of removed axillary lymphnodes in high risk breast cancer patients influence the survival?

Ebner F, Wöckel A, Schwentner L, Blettner M, Janni W, Kreienberg R, Wischnewsky M.

BMC Cancer. 2019 Jan 18;19(1):90. doi: 10.1186/s12885-019-5292-2.

6.

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 2 with Recommendations for the Therapy of Primary, Recurrent and Advanced Breast Cancer.

Wöckel A, Festl J, Stüber T, Brust K, Krockenberger M, Heuschmann PU, Jírů-Hillmann S, Albert US, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Baumgartner T, Kreipe HH, Knoefel WT, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch HH, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn HP, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann MW, Blohmer J, Fasching P, Lux MP, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück HJ, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Buck A, Stangl S.

Geburtshilfe Frauenheilkd. 2018 Nov;78(11):1056-1088. doi: 10.1055/a-0646-4630. Epub 2018 Nov 26.

7.

Interdisciplinary Screening, Diagnosis, Therapy and Follow-up of Breast Cancer. Guideline of the DGGG and the DKG (S3-Level, AWMF Registry Number 032/045OL, December 2017) - Part 1 with Recommendations for the Screening, Diagnosis and Therapy of Breast Cancer.

Wöckel A, Festl J, Stüber T, Brust K, Stangl S, Heuschmann PU, Albert US, Budach W, Follmann M, Janni W, Kopp I, Kreienberg R, Kühn T, Langer T, Nothacker M, Scharl A, Schreer I, Link H, Engel J, Fehm T, Weis J, Welt A, Steckelberg A, Feyer P, König K, Hahne A, Kreipe HH, Knoefel WT, Denkinger M, Brucker S, Lüftner D, Kubisch C, Gerlach C, Lebeau A, Siedentopf F, Petersen C, Bartsch HH, Schulz-Wendtland R, Hahn M, Hanf V, Müller-Schimpfle M, Henscher U, Roncarati R, Katalinic A, Heitmann C, Honegger C, Paradies K, Bjelic-Radisic V, Degenhardt F, Wenz F, Rick O, Hölzel D, Zaiss M, Kemper G, Budach V, Denkert C, Gerber B, Tesch H, Hirsmüller S, Sinn HP, Dunst J, Münstedt K, Bick U, Fallenberg E, Tholen R, Hung R, Baumann F, Beckmann MW, Blohmer J, Fasching PA, Lux MP, Harbeck N, Hadji P, Hauner H, Heywang-Köbrunner S, Huober J, Hübner J, Jackisch C, Loibl S, Lück HJ, von Minckwitz G, Möbus V, Müller V, Nöthlings U, Schmidt M, Schmutzler R, Schneeweiss A, Schütz F, Stickeler E, Thomssen C, Untch M, Wesselmann S, Bücker A, Krockenberger M.

Geburtshilfe Frauenheilkd. 2018 Oct;78(10):927-948. doi: 10.1055/a-0646-4522. Epub 2018 Oct 19.

8.

The Screening, Diagnosis, Treatment, and Follow-Up of Breast Cancer.

Wöckel A, Albert US, Janni W, Scharl A, Kreienberg R, Stüber T.

Dtsch Arztebl Int. 2018 May 4;115(18):316-323. doi: 10.3238/arztebl.2018.0316.

9.
10.

Is extracapsular nodal extension in sentinel nodes a predictor for nonsentinel metastasis and is there an impact on survival parameters?-A retrospective single center cohort study with 324 patients.

Schwentner L, Dayan D, Wöckel A, Janni W, Kreienberg R, Blettner M, Wollschläger D.

Breast J. 2018 Jul;24(4):480-486. doi: 10.1111/tbj.12983. Epub 2017 Dec 19.

PMID:
29265572
11.

["Deciding wisely together" - an initiative of the Association of the Scientific Medical Societies in Germany: Mission, methodology and application].

Nothacker M, Kreienberg R, Kopp IB.

Z Evid Fortbild Qual Gesundhwes. 2017 Dec;129:3-11. doi: 10.1016/j.zefq.2017.10.012. Epub 2017 Nov 20. German.

PMID:
29157559
12.

Corrections to "Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression".

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2017 Nov;28(11):2899. doi: 10.1093/annonc/mdw349. Epub 2019 Dec 4. No abstract available.

PMID:
32014233
13.

Geriatric assessment and biomarkers in patients with metastatic breast cancer receiving first-line mono-chemotherapy: Results from the randomized phase III PELICAN trial.

Honecker F, Harbeck N, Schnabel C, Wedding U, Waldenmaier D, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba B, Dorn J, Warm M, Al-Batran SE, de Wit M; PELICAN investigators.

J Geriatr Oncol. 2018 Mar;9(2):163-169. doi: 10.1016/j.jgo.2017.09.009. Epub 2017 Oct 18.

PMID:
29055624
14.

Comorbidity-dependent adherence to guidelines and survival in breast cancer-Is there a role for guideline adherence in comorbid breast cancer patients? A retrospective cohort study with 2137 patients.

Wollschläger D, Meng X, Wöckel A, Janni W, Kreienberg R, Blettner M, Schwentner L.

Breast J. 2018 Mar;24(2):120-127. doi: 10.1111/tbj.12855. Epub 2017 Jul 7.

PMID:
28685896
15.

Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival.

Ebner F, Wöckel A, Janni W, Kreienberg R, Schwentner L, Wischnewsky M.

J Cancer Res Clin Oncol. 2017 Sep;143(9):1823-1831. doi: 10.1007/s00432-017-2425-3. Epub 2017 Apr 24.

PMID:
28439713
16.

Predictors of the course of quality of life during therapy in women with primary breast cancer.

Wöckel A, Schwentner L, Krockenberger M, Kreienberg R, Janni W, Wischnewsky M, Thorsten K, Felix F, Riccardo F, Blettner M, Singer S.

Qual Life Res. 2017 Aug;26(8):2201-2208. doi: 10.1007/s11136-017-1570-0. Epub 2017 Apr 6.

PMID:
28386772
17.

Are There Breast Cancer Patients with Node-Negative Small Tumours, Who Do Not Benefit from Adjuvant Systemic Therapy?

Stüber T, Novopashenny I, Diessner J, Bartmann C, Stein R, Krockenberger M, Häusler S, Janni W, Kreienberg R, Blettner M, Wöckel A, Wischnewsky M.

Oncology. 2017;92(6):317-324. doi: 10.1159/000455050. Epub 2017 Mar 24.

PMID:
28334705
18.

Do Patients with Luminal A Breast Cancer Profit from Adjuvant Systemic Therapy? A Retrospective Multicenter Study.

Diessner J, Wischnewsky M, Blettner M, Häusler S, Janni W, Kreienberg R, Stein R, Stüber T, Schwentner L, Bartmann C, Wöckel A.

PLoS One. 2016 Dec 19;11(12):e0168730. doi: 10.1371/journal.pone.0168730. eCollection 2016.

19.

Pattern of metastatic spread and subcategories of breast cancer.

Bartmann C, Wischnewsky M, Stüber T, Stein R, Krockenberger M, Häusler S, Janni W, Kreienberg R, Blettner M, Schwentner L, Wöckel A, Diessner J.

Arch Gynecol Obstet. 2017 Jan;295(1):211-223. doi: 10.1007/s00404-016-4225-4. Epub 2016 Nov 10.

PMID:
27832352
20.

Factors influencing the development of visceral metastasis of breast cancer: A retrospective multi-center study.

Bartmann C, Diessner J, Blettner M, Häusler S, Janni W, Kreienberg R, Krockenberger M, Schwentner L, Stein R, Stüber T, Wöckel A, Wischnewsky M.

Breast. 2017 Feb;31:66-75. doi: 10.1016/j.breast.2016.10.016. Epub 2016 Nov 2.

PMID:
27816834
21.

A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.

Harbeck N, Saupe S, Jäger E, Schmidt M, Kreienberg R, Müller L, Otremba BJ, Waldenmaier D, Dorn J, Warm M, Scholz M, Untch M, de Wit M, Barinoff J, Lück HJ, Harter P, Augustin D, Harnett P, Beckmann MW, Al-Batran SE; PELICAN Investigators.

Breast Cancer Res Treat. 2017 Jan;161(1):63-72. doi: 10.1007/s10549-016-4033-3. Epub 2016 Oct 31.

22.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2017 Nov 1;28(11):2899. doi: 10.1093/annonc/mdw349. No abstract available.

23.

[Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation].

Beckmann MW, Sell C, Aydogdu M, Brucker SY, Fehm T, Janni W, Kreienberg R, Kümmel S, Neumann M, Scharl A, Schleicher B, Wallwiener D, Wöckel A, Fasching PA, Lux MP.

Gesundheitswesen. 2016 Jul;78(7):e52. doi: 10.1055/s-0042-113351. Epub 2016 Jul 29. German. No abstract available.

PMID:
27472087
24.

The impact of breast cancer biological subtyping on tumor size assessment by ultrasound and mammography - a retrospective multicenter cohort study of 6543 primary breast cancer patients.

Stein RG, Wollschläger D, Kreienberg R, Janni W, Wischnewsky M, Diessner J, Stüber T, Bartmann C, Krockenberger M, Wischhusen J, Wöckel A, Blettner M, Schwentner L; BRENDA Study Group.

BMC Cancer. 2016 Jul 13;16:459. doi: 10.1186/s12885-016-2426-7.

25.

[Good Prognosis! Breast Cancer Update 2016].

Krockenberger M, Wöckel A, Kreienberg R.

MMW Fortschr Med. 2016 Jun 9;158(11):58-62; quiz 63-4. doi: 10.1007/s15006-016-7660-z. Review. German. No abstract available.

PMID:
27271417
26.

Which patient- and physician-related factors are associated with guideline adherent initiation of adjuvant endocrine therapy? Results of the prospective multi-centre cohort study BRENDA II.

Stüber T, van Ewijk R, Diessner J, Kühn T, Flock F, Felberbaum R, Blettner M, Kreienberg R, Janni W, Wöckel A, Singer S, Schwentner L.

Breast Cancer. 2017 Mar;24(2):281-287. doi: 10.1007/s12282-016-0701-8. Epub 2016 May 19.

PMID:
27193566
27.

Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.

Diessner J, Wischnewsky M, Stüber T, Stein R, Krockenberger M, Häusler S, Janni W, Kreienberg R, Blettner M, Schwentner L, Wöckel A, Bartmann C.

BMC Cancer. 2016 May 12;16:307. doi: 10.1186/s12885-016-2345-7.

28.

Do T1a breast cancers profit from adjuvant systemic therapy? A multicenter retrospective cohort study of 325 T1a-patients.

Wolters R, Ebner F, Janni W, Novopashenny I, Wöckel A, Kreienberg R, Wischnewsky M, Schwentner L; Brenda study group.

Arch Gynecol Obstet. 2016 Aug;294(2):377-84. doi: 10.1007/s00404-016-4016-y. Epub 2016 Feb 19.

PMID:
26894302
29.

Exploring patient- and physician-related factors preventing breast cancer patients from guideline-adherent adjuvant chemotherapy-results from the prospective multi-center study BRENDA II.

Schwentner L, Van Ewijk R, Kühn T, Flock F, Felberbaum R, Blettner M, Kreienberg R, Janni W, Wöckel A, Singer S.

Support Care Cancer. 2016 Jun;24(6):2759-66. doi: 10.1007/s00520-016-3088-3. Epub 2016 Jan 27.

PMID:
26816089
30.

Reply to Schrodi et al. 2015.

Kowalski C, Wesselmann S, Kuhr K, Wallwiener D, Kreienberg R.

Breast J. 2015 Nov-Dec;21(6):699-701. doi: 10.1111/tbj.12514. Epub 2015 Sep 22. No abstract available.

PMID:
26391618
31.

[Documentation Time and Effort and Associated Resources for Patients with Primary Breast Cancer from Diagnosis to End of Follow-Up - Results of a Multicentre Validation].

Beckmann M, Sell C, Aydogdu M, Brucker SY, Fehm T, Janni W, Kreienberg R, Kümmel S, Neumann M, Scharl A, Schleicher B, Wallwiener D, Wöckel A, Fasching PA, Lux MP.

Gesundheitswesen. 2016 Jul;78(7):438-45. doi: 10.1055/s-0035-1554707. Epub 2015 Aug 6. German. Erratum in: Gesundheitswesen. 2016 Jul;78(7):e52.

PMID:
26250614
32.

Breast Cancer Patients' Fear of Treatment: Results from the Multicenter Longitudinal Study BRENDA II.

Singer S, Blettner M, Kreienberg R, Janni W, Wöckel A, Kühn T, Felberbaum R, Flock F, Schwentner L; BRENDA II study group.

Breast Care (Basel). 2015 Apr;10(2):95-100. doi: 10.1159/000381933.

33.

Guidelines are advantageous, though not essential for improved survival among breast cancer patients.

Wolters R, Wischhusen J, Stüber T, Weiss CR, Krockberger M, Bartmann C, Blettner M, Janni W, Kreienberg R, Schwentner L, Novopashenny I, Wischnewsky M, Wöckel A, Diessner J.

Breast Cancer Res Treat. 2015 Jul;152(2):357-66. doi: 10.1007/s10549-015-3484-2. Epub 2015 Jun 24.

PMID:
26105798
34.

Aggressive Intrinsic Subtypes in Breast Cancer: A Predictor of Guideline Adherence in Older Patients With Breast Cancer?

Ebner F, Hancke K, Blettner M, Schwentner L, Wöckel A, Kreienberg R, Janni W, van Ewijk R.

Clin Breast Cancer. 2015 Aug;15(4):e189-95. doi: 10.1016/j.clbc.2015.03.003. Epub 2015 Mar 23.

PMID:
25913904
35.

Identifying the impact of inflammatory breast cancer on survival: a retrospective multi-center cohort study.

Diessner J, Van Ewijk R, Weiss CR, Janni W, Wischnewsky MB, Kreienberg R, Hancke K, Blettner M, Wöckel A, Schwentner L.

Arch Gynecol Obstet. 2015 Sep;292(3):655-64. doi: 10.1007/s00404-015-3691-4. Epub 2015 Mar 27.

PMID:
25814296
36.

Tumor biology in older breast cancer patients--what is the impact on survival stratified for guideline adherence? A retrospective multi-centre cohort study of 5378 patients.

Ebner F, van Ewijk R, Wöckel A, Hancke K, Schwentner L, Fink V, Kreienberg R, Janni W, Blettner M.

Breast. 2015 Jun;24(3):256-62. doi: 10.1016/j.breast.2015.02.029. Epub 2015 Mar 11.

PMID:
25769974
37.

Predicting fatigue in older breast cancer patients receiving radiotherapy. A head-to-head comparison of established assessments.

Denkinger MD, Hasch M, Gerstmayer A, Kreienberg R, Nikolaus T, Hancke K.

Z Gerontol Geriatr. 2015 Feb;48(2):128-34. doi: 10.1007/s00391-014-0840-5. Epub 2015 Jan 16.

PMID:
25592175
38.

Does patient education work in breast cancer? Final results from the global CARIATIDE study.

Markopoulos C, Neven P, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P, Barni S, Deschamp V.

Future Oncol. 2015;11(2):205-17. doi: 10.2217/fon.14.179.

PMID:
25591836
39.

Radiotherapy effects on early breast cancer survival in observational and randomized studies: a systematic analysis of advantages, disadvantages and differences between the two study types.

König J, van Ewijk R, Kuhr K, Schmidberger H, Wöckel A, Kreienberg R, Blettner M.

Breast Cancer. 2016 May;23(3):415-24. doi: 10.1007/s12282-014-0579-2. Epub 2015 Jan 14.

PMID:
25585654
40.

Quality of care in breast cancer centers: results of benchmarking by the German Cancer Society and German Society for Breast Diseases.

Kowalski C, Ferencz J, Brucker SY, Kreienberg R, Wesselmann S.

Breast. 2015 Apr;24(2):118-23. doi: 10.1016/j.breast.2014.11.014. Epub 2014 Dec 13.

PMID:
25515645
41.

Response to: Importance of work-life balance among German medical students who wish to become gynecologists.

Hancke K, Igl W, Toth B, Bühren A, Ditsch N, Kreienberg R.

Arch Gynecol Obstet. 2015 Feb;291(2):241. doi: 10.1007/s00404-014-3530-z. No abstract available.

PMID:
25384518
42.
43.

Concentration of gynaecology and obstetrics in Germany: is comprehensive access at stake?

Mennicken R, Kolodziej IW, Augurzky B, Kreienberg R.

Health Policy. 2014 Dec;118(3):396-406. doi: 10.1016/j.healthpol.2014.07.017. Epub 2014 Aug 2.

PMID:
25201487
44.

Is guideline-adherent adjuvant treatment an equal alternative for patients aged >65 who cannot participate in adjuvant clinical breast cancer trials? A retrospective multi-center cohort study of 4,142 patients.

Van Ewijk R, Wöckel A, Gundelach T, Hancke K, Janni W, Singer S, Kreienberg R, Blettner M, Schwentner L.

Arch Gynecol Obstet. 2015 Mar;291(3):631-40. doi: 10.1007/s00404-014-3438-7. Epub 2014 Sep 2.

PMID:
25178186
45.

DGGG Guidelines Programme: Status Quo - Quo Vadis!

Beckmann MW, Linde I, Bütof C, Kreienberg R, Gass P.

Geburtshilfe Frauenheilkd. 2014 Mar;74(3):251-259.

46.

Final analysis of the prospective WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) early breast cancer: efficacy and predictive value of Ki67 expression.

Nitz U, Gluz O, Huober J, Kreipe HH, Kates RE, Hartmann A, Erber R, Moustafa Z, Scholz M, Lisboa B, Mohrmann S, Möbus V, Augustin D, Hoffmann G, Weiss E, Böhmer S, Kreienberg R, Du Bois A, Sattler D, Thomssen C, Kiechle M, Jänicke F, Wallwiener D, Harbeck N, Kuhn W.

Ann Oncol. 2014 Aug;25(8):1551-7. doi: 10.1093/annonc/mdu186. Epub 2014 May 14. Erratum in: Ann Oncol. 2017 Nov 1;28(11):2899. Ann Oncol. 2017 Nov;28(11):2899.

47.
48.

Sentinel node biopsy and axillary dissection in breast cancer: the evidence and its limits.

Janni W, Kühn T, Schwentner L, Kreienberg R, Fehm T, Wöckel A.

Dtsch Arztebl Int. 2014 Apr 4;111(14):244-9. doi: 10.3238/arztebl.2014.0244. Review.

49.

The impact of educational materials on compliance and persistence rates with adjuvant aromatase inhibitor treatment: first-year results from the compliance of aromatase inhibitors assessment in daily practice through educational approach (CARIATIDE) study.

Neven P, Markopoulos C, Tanner M, Marty M, Kreienberg R, Atkins L, Franquet A, Gnant M, Neciosup S, Tesarova P, Barni S, Deschamp V.

Breast. 2014 Aug;23(4):393-9. doi: 10.1016/j.breast.2014.02.009. Epub 2014 Mar 24.

50.

Response.

Moebus V, Jackisch C, Schneeweiss A, Huober J, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, Kuhn W, Nitz UA, Runnebaum IB, Hinke A, Kreienberg R, Untch M; AGO Breast Study Group.

J Natl Cancer Inst. 2014 Mar;106(3):djt452. doi: 10.1093/jnci/djt452. Epub 2014 Feb 28. No abstract available.

PMID:
24586093

Supplemental Content

Loading ...
Support Center